A commission called on U.S. lawmakers to act quickly to prevent an “overdependence” on China that could leave American patients “vulnerable to supply chain weaponization.”
Even before the release of its latest biotech plan, China’s rise as a global pharmaceutical powerhouse had already rung alarm bells in Congress as well as the corporate suites of top drugmakers. Its new goal of ensuring the country produces a quarter of the world’s “first-in-class drugs” by 2030 has intensified concerns that the U.S. might soon lose a long-held edge and become overly dependent on China for new medicines.
The commission, an 11-member group that includes members of Congress, was formed by defense appropriations legislation in 2022 to study the state of biotechnology competition between the U.S. and other countries, particularly China. Its goal is to promote legislation to support the biotech industry, much as work by an earlier commission helped pave the way for the 2022 CHIPS Act aimed at semiconductor manufacturing and research.
The latest publication focuses on the kind of cross-border licensing deals that have become commonplace over the last few years. A large proportion of these transactions are based on preclinical research and are rising in value, signaling “a growing trust in China’s ability to innovate in the pharmaceutical sector.” The commission also pointed to “escalating deal structures” and repeat collaborations, which could transfer to China-based partners key knowledge such as “development, commercialization, and regulatory best practices for U.S. markets.”
S. joint ventures into Chinese markets in the automobile, semiconductor, and industrial chemical sectors.
Source link







